Status:
COMPLETED
Angiotensin Converting Enzyme Inhibitors & Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization
Lead Sponsor:
Hamilton Health Sciences Corporation
Conditions:
Kidney Failure
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine if patients should stop taking their angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) around the time of their angiogram in...
Detailed Description
There are approximately 4000 coronary angiograms performed annually at the Hamilton General Hospital to diagnose and treat coronary artery disease. Many of the patients undergoing this procedure have ...
Eligibility Criteria
Inclusion
- Scheduled for Angiography in \>= 24hrs from enrolment
- Documented Cr \>= 150 within 3 months before cardiac catheterization AND/OR documented Cr \>= 132umol/L within 1 week Before Cardiac Catheterization
- Currently Taking an ACE Inhibitor
Exclusion
- Patients with end stage renal disease (for example, patient on dialysis)
- Emergency Cardiac Catheterization with insufficient time to hold the ACEI
- Acute Pulmonary Edema
Key Trial Info
Start Date :
July 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT00317252
Start Date
July 1 2006
End Date
March 1 2012
Last Update
October 22 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamilton General Hospital
Hamilton, Ontario, Canada, L8L 2X2